Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Monika, Ciesielska"'
Autor:
Christina M. Mingora, Bryan A. Garcia, Kevin C. Mange, Dayton W. Yuen, Monika Ciesielska, Jakko van Ingen, Patrick A. Flume, Susan E. Dorman
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mycobacterial time to positivity (TTP) in liquid culture media has predictive value for longer term outcomes in pulmonary tuberculosis, but has not been thoroughly studied in nontuberculous mycobacterial pulmonary disease. This st
Externí odkaz:
https://doaj.org/article/7b1d4996b7d64463afa4fa76822397c2
Autor:
Theodore K. Marras, Mariam Hassan, Kevin C. Mange, Monika Ciesielska, Shilpa Dhar Murthy, Zhanna Jumadilova, Anjan Chatterjee
Publikováno v:
ERJ Open Research, Vol 8, Iss 3 (2022)
Externí odkaz:
https://doaj.org/article/cbc83b69f5b94fd3a566773c04c2a933
Autor:
Timothy R. Aksamit, Richard J. Wallace, Dayton W. Yuen, Kozo Morimoto, Wouter Hoefsloot, David E. Griffith, Doreen Addrizzo-Harris, Kevin L. Winthrop, Kevin C. Mange, Monika Ciesielska, Rachel Thomson, Jakko van Ingen, Chris Coulter, Stephen K. Field, Patrick A. Flume, Barbara A. Brown-Elliott
Publikováno v:
Chest. 160:831-842
Background: In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bce5263ae6c0f4e6424f8686ff8b0332
https://doi.org/10.1016/j.chest.2021.03.070
https://doi.org/10.1016/j.chest.2021.03.070
Autor:
Theodore K, Marras, Mariam, Hassan, Kevin C, Mange, Monika, Ciesielska, Shilpa Dhar, Murthy, Zhanna, Jumadilova, Anjan, Chatterjee
Publikováno v:
ERJ open research. 8(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a6984a8f54dd346d088b1fbf2462924f
https://pubmed.ncbi.nlm.nih.gov/35821755
https://pubmed.ncbi.nlm.nih.gov/35821755
Autor:
Christina M. Mingora, Bryan A. Garcia, Kevin C. Mange, Dayton W. Yuen, Monika Ciesielska, Jakko van Ingen, Patrick A. Flume, Susan E. Dorman
Publikováno v:
BMC Infectious Diseases, 22, 1
BMC Infectious Diseases, 22
BMC Infectious Diseases, 22
Background Mycobacterial time to positivity (TTP) in liquid culture media has predictive value for longer term outcomes in pulmonary tuberculosis, but has not been thoroughly studied in nontuberculous mycobacterial pulmonary disease. This study sough
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8686f00447069a81efd61089ef1c29ee
https://pubmed.ncbi.nlm.nih.gov/35279081
https://pubmed.ncbi.nlm.nih.gov/35279081
Autor:
Stephen J. Ruoss, David E. Griffith, Dayton W. Yuen, Jakko van Ingen, Kozo Morimoto, Patrick A. Flume, Kevin C. Mange, Chris Coulter, Rachel Thomson, Theodore K. Marras, Monika Ciesielska, Luigi Codecasa, Richard J. Wallace, Barbara A. Brown-Elliott, Jae-Joon Yim, Kevin L. Winthrop
Publikováno v:
Annals of the American Thoracic Society, 18, 7, pp. 1147-1157
Annals of the American Thoracic Society, 18, 1147-1157
Annals of the American Thoracic Society, 18, 1147-1157
Contains fulltext : 238192.pdf (Publisher’s version ) (Open Access) Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (AL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a803a60eeca12a027456d42824da9e3
Autor:
David E, Griffith, Rachel, Thomson, Patrick A, Flume, Timothy R, Aksamit, Stephen K, Field, Doreen J, Addrizzo-Harris, Kozo, Morimoto, Wouter, Hoefsloot, Kevin C, Mange, Dayton W, Yuen, Monika, Ciesielska, Richard J, Wallace, Jakko, van Ingen, Barbara A, Brown-Elliott, Chris, Coulter, Kevin L, Winthrop
Publikováno v:
Chest. 160(3)
In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobacterium avium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd90ae37412e073fc03f1a970ae565b7
https://pubmed.ncbi.nlm.nih.gov/33887244
https://pubmed.ncbi.nlm.nih.gov/33887244
Autor:
Kevin L, Winthrop, Patrick A, Flume, Rachel, Thomson, Kevin C, Mange, Dayton W, Yuen, Monika, Ciesielska, Kozo, Morimoto, Stephen J, Ruoss, Luigi R, Codecasa, Jae-Joon, Yim, Theodore K, Marras, Jakko, van Ingen, Richard J, Wallace, Barbara A, Brown-Elliott, Chris, Coulter, David E, Griffith
Publikováno v:
Annals of the American Thoracic Society
Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) increased culture conversio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1e027d96f5403f3f51bd7998d0282351
https://pubmed.ncbi.nlm.nih.gov/33326356
https://pubmed.ncbi.nlm.nih.gov/33326356
Autor:
Ivanka Galeva, Zhanna Jumadilova, Monika Ciesielska, Amparo Solé, Alexandra L. Quittner, Predrag Minic, Marco Cipolli, Isabelle Fajac, John P. Clancy, Diana Bilton, Dorota Sands, Tacjana Pressler, Michael W. Konstan
Publikováno v:
J Cyst Fibros
Background . In CLEAR-108—a phase 3, randomised, open-label study—once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic fib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3538e60b3fa0cb104b0cdc3a4a8ac6
https://pubmed.ncbi.nlm.nih.gov/34144923
https://pubmed.ncbi.nlm.nih.gov/34144923
Autor:
Thompson Olaoni, Chandan Saha, Claire N. Harrison, Monika Ciesielska, Yurina Miki, Priya Sriskandarajah, Jennifer O'Sullivan, Chienye Asinobi, Deepti Radia, Donal P. McLornan, Clare Oni, Claire Woodley, Rebecca Todd, Anna Green, Mark Ong, Susan Asirvatham, Clive Grattan, Natalia Curto-Garcia
Publikováno v:
Blood. 138:3625-3625
Background: Systemic mastocytosis (SM) is a disorder of neoplastic mast cells ranging from indolent to aggressive multi-system disease. We previously reported our large single centre experience managing SM. Since 2019 patients have had access to new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c744c96472b6304d4d66fe1acfa9b4c7
https://doi.org/10.1182/blood-2021-152234
https://doi.org/10.1182/blood-2021-152234